Mirum Pharamceuticals (MIRM) PT Raised to $39 at Baird

Baird analyst Brian Skorney raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $39.00 (from $34.00) while maintaining a Outperform rating.

The analyst commented: "Raising target price on positive volixibat results. Volixibat demonstrated unprecedented reductions in pruritis in the Phase 2 VANTAGE study in PBC, opening the door for a competitive profile in PBC and a clear road to approval in PSC. We believe these results are better than expected, with the itch reductions surpassing what has been seen from seladelpar. As a result we are increasing our probability of success for volixibat across these two indications and raising our target price to $39."

You May Also Be Interested In

• Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
• Kotak Upgrades Narayana Hrudayalaya Ltd (NARH:IN) to Buy (1)
• Walmart (WMT) PT Lowered to $125 at JPMorgan, Overweight Rating Maintained as 'Short Case Feels Greedy'